Browsing Tag
Pelacarsen
2 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
Novartis pelacarsen fails 8,323-patient Phase III test despite lowering Lp(a)
Novartis’ pelacarsen has failed the primary endpoint in the 8,323-patient Phase III Lp(a)HORIZON trial despite lowering lipoprotein(a), delivering a major setback to one of cardiovascular medicine’s most closely watched drug-development hypotheses and raising new questions for competing Lp(a)-lowering programmes.